Full Text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Scientific studies have provided evidence that there is a relationship between violent and aggressive behaviors and addictions. Genes involved with the reward system, specifically the brain reward cascade (BRC), appear to be associated with various addictions and impulsive, aggressive, and violent behaviors. In our previous research, we examined the Taq A1 allele (variant D2 dopamine receptor gene) and the DAT-40 base repeat (a variant of the dopamine transporter gene) in 11 Caucasian boys at the Brown School in San Marcus, Texas, diagnosed with intermittent explosive disorder. Thirty supernormal controls were screened to exclude several reward–deficit behaviors, including pathological violence, and genotyped for the DRD2 gene. Additionally, 91 controls were screened to exclude ADHD, pathological violence, alcoholism, drug dependence, and tobacco abuse, and their results were compared with DAT1 genotype results. In the schoolboys vs. supercontrols, there was a significant association with the D2 variant and a trend with the dopamine transporter variant. Results support our hypothesis and the involvement of at least two gene risk alleles with adolescent violent/aggressive behaviors. This study and the research presented in this paper suggest that violent/aggressive behaviors are associated with a greater risk of addiction, mediated via various genes linked to the BRC. This review provides a contributory analysis of how gene polymorphisms, especially those related to the brain reward circuitry, are associated with violent behaviors.

Details

Title
Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing
Author
Modestino, Edward Justin 1   VIAFID ORCID Logo  ; Blum, Kenneth 2   VIAFID ORCID Logo  ; Dennen, Catherine A 3 ; Downs, B William 4   VIAFID ORCID Logo  ; Bagchi, Debasis 5   VIAFID ORCID Logo  ; Llanos-Gomez, Luis 6 ; Elman, Igor 7 ; Baron, David 8 ; Thanos, Panayotis K 9 ; Badgaiyan, Rajendra D 10   VIAFID ORCID Logo  ; Braverman, Eric R 6 ; Gupta, Ashim 11   VIAFID ORCID Logo  ; Gold, Mark S 12 ; Abdalla Bowirrat 13   VIAFID ORCID Logo 

 The Kenneth Blum Behavioral & Neurogenetic Institute, Austin, TX 78701, USA; Department of Psychology, Curry College, Milton, MA 02360, USA 
 The Kenneth Blum Behavioral & Neurogenetic Institute, Austin, TX 78701, USA; Division of Addiction Research & Education, Center for Psychiatry, Medicine & Primary Care, Western University Health Sciences, Pomona, CA 91766, USA; Department of Precision Behavioral Management, Geneus Health, San Antonio, TX 78283, USA; Institute of Psychology, ELTE Eötvös Loránd University, H-1053 Budapest, Hungary; Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA; Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur 721172, West Bengal, India; Department of Psychiatry, Wright State University Boonshoft School of Medicine and Dayton VA Medical Centre, Dayton, OH 45324, USA; Department of Psychiatry, School of Medicine, University of Vermont, Burlington, VT 05405, USA; Department of Molecular Biology and Adelson, School of Medicine, Ariel University, Ariel 40700, Israel 
 Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA 08033, USA 
 Division of Nutrigenomics, Victory Nutrition International, Lederach, PA 19438, USA 
 Division of Nutrigenomics, Victory Nutrition International, Lederach, PA 19438, USA; Department of Pharmacy and Health Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA 
 The Kenneth Blum Behavioral & Neurogenetic Institute, Austin, TX 78701, USA 
 Department of Psychiatry, Harvard Medical School, Boston, MA 02139, USA 
 Division of Addiction Research & Education, Center for Psychiatry, Medicine & Primary Care, Western University Health Sciences, Pomona, CA 91766, USA 
 Department of Psychology & Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA), Research Institute on Addictions, University at Buffalo, Buffalo, NY 14203, USA 
10  Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital, Long School of Medicine, University of Texas Medical Center, San Antonio, TX 78229, USA 
11  Future Biologics, Lawrenceville, GA 30043, USA 
12  Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA 
13  Department of Molecular Biology and Adelson, School of Medicine, Ariel University, Ariel 40700, Israel 
First page
1946
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
20754426
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2756734950
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.